Windlas Biotech Submits Q4 FY26 Certificate Under SEBI Depositories Regulations

1 min read     Updated on 06 Apr 2026, 05:34 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Windlas Biotech Limited submitted its Q4 FY26 certificate under SEBI Depositories Regulations on April 6, 2026. The certificate from MUFG Intime India Private Limited confirmed no demat requests were received during the quarter ended March 31, 2026, as the company has no physical shares outstanding.

powered bylight_fuzz_icon
37022654

*this image is generated using AI for illustrative purposes only.

Windlas biotech Limited has filed its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The pharmaceutical company submitted the mandatory documentation to both BSE and NSE on April 6, 2026.

Quarterly Compliance Certificate Details

The certificate was issued by MUFG Intime India Private Limited (formerly Link Intime India Private Limited), which serves as the company's Registrar and Share Transfer Agent. The document pertains to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.

Parameter: Details
Quarter Period: March 31, 2026
Certificate Date: April 03, 2026
Filing Date: April 06, 2026
Registrar: MUFG Intime India Private Limited

Key Confirmation

MUFG Intime India Private Limited confirmed that during the quarter ended March 31, 2026, no demat requests were received for processing. The registrar specifically noted that Windlas Biotech Limited does not have any physical shares outstanding, indicating that all shares are already in dematerialized form.

Regulatory Compliance

The submission was made to the compliance departments of both major Indian stock exchanges. Company Secretary and Compliance Officer Ananta Narayan Panda signed the filing letter, ensuring adherence to regulatory requirements. This quarterly certificate filing is a standard compliance requirement for listed companies under SEBI regulations.

Company Information

Windlas Biotech Limited operates from its registered office in Dehradun, Uttarakhand, with its corporate office located in Gurgaon, Haryana. The company maintains its listing on both BSE and NSE, trading under the symbols 543329 and WINDLAS respectively.

How might Windlas Biotech's complete dematerialization of shares impact its future capital raising activities and investor accessibility?

What strategic initiatives is Windlas Biotech likely to pursue in the pharmaceutical sector following this clean compliance record?

Will the transition from Link Intime to MUFG Intime as registrar bring enhanced digital services or operational efficiencies for shareholders?

Windlas Biotech Shareholders Approve Re-appointment of Three Directors Through Postal Ballot

1 min read     Updated on 20 Mar 2026, 12:58 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Windlas Biotech Limited successfully completed its postal ballot process with shareholders approving the re-appointment of three directors - Whole-time Director Ashok Kumar Windlass and Independent Directors Vivek Dhariwal and Gaurav Gulati. The voting demonstrated overwhelming support with 15320883 votes in favour and only 2 votes against across all resolutions.

powered bylight_fuzz_icon
35536507

*this image is generated using AI for illustrative purposes only.

Windlas Biotech Limited has successfully concluded its postal ballot process, with shareholders overwhelmingly approving the re-appointment of three directors through special resolutions. The pharmaceutical company announced the results on March 20, 2026, following the completion of remote e-voting that concluded on March 19, 2026.

Director Re-appointments Approved

Shareholders approved three key director re-appointments with requisite majority support:

Position: Director Name DIN Effective Date
Whole-time Director Mr. Ashok Kumar Windlass 00011451 May 3, 2026
Independent Director Mr. Vivek Dhariwal 02826679 May 6, 2026
Independent Director Mr. Gaurav Gulati 02308392 May 6, 2026

Voting Results and Participation

The postal ballot process demonstrated strong shareholder support across all three resolutions. The remote e-voting period remained open from February 18, 2026, at 9:00 A.M. to March 19, 2026, at 5:00 P.M.

Voting Parameter: Details
Total Shareholders (Cut-off Date) 45,610
Cut-off Date February 13, 2026
Members Participated 111
Total Votes Cast 15320885
Votes in Favour 15320883
Votes Against 2
Voting Percentage 72.69%

Resolution-wise Voting Breakdown

All three special resolutions received identical voting results, reflecting unanimous support from participating shareholders:

Resolution 1: Re-appointment of Mr. Ashok Kumar Windlass

  • Promoter Group Participation: 13065352 votes (100.00% in favour)
  • Public Institutions: 2159125 votes (100.00% in favour)
  • Public Non-Institutions: 96406 votes in favour, 2 votes against (99.9979% in favour)

Resolutions 2 & 3: Independent Directors Re-appointment

Both Mr. Vivek Dhariwal and Mr. Gaurav Gulati's re-appointments as Independent Directors received identical voting patterns, with promoter groups not being interested parties in these resolutions as per regulatory requirements.

Regulatory Compliance and Process

The postal ballot was conducted pursuant to Section 110 of the Companies Act, 2013, and related rules. Sandeep Joshi, Practicing Company Secretary, served as the Scrutinizer for the process, ensuring fair and transparent voting procedures.

The company has made the voting results and Scrutinizer's report available on its website at www.windlas.com and on the website of MUFG Intime India Private Limited, the agency that provided e-voting facilities. Company Secretary Ananta Narayan Panda signed the results notification, confirming compliance with Regulation 30 of SEBI Listing Regulations.

What strategic initiatives might the re-appointed leadership team pursue to drive Windlas Biotech's growth in the competitive pharmaceutical market?

How could the strong shareholder confidence demonstrated in this voting process impact Windlas Biotech's ability to raise capital for future expansion plans?

Will the renewed leadership stability influence Windlas Biotech's approach to potential mergers, acquisitions, or strategic partnerships in 2026?

More News on Windlas Biotech